- $99.24m
- $68.35m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.78 | ||
| Price to Tang. Book | 3.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12,405.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -112.63% | ||
| Return on Equity | -130.58% | ||
| Operating Margin | -391575% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 11.07 | 0.17 | 0.01 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 4th, 2001
- Public Since
- January 26th, 2023
- No. of Shareholders
- 1,026
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 37,734,967
- Address
- 2625 Townsgate Road, Suite 230, WESTLAKE VILLAGE, 91361
- Web
- https://genelux.com/
- Phone
- +1 8052679889
- Contact
- Ankit Bhargava
- Auditors
- WEINBERG & COMPANY PA
Upcoming Events for GNLX
Similar to GNLX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Genelux share price?
As of Today at 20:48 UTC, shares in Genelux are trading at $2.63. This share price information is delayed by 15 minutes.
How has the Genelux share price performed this year?
Shares in Genelux last closed at $2.63 and the price had moved by -24.43% over the past 365 days. In terms of relative price strength the Genelux share price has underperformed the S&P500 Index by -31.85% over the past year.
What are the analyst and broker recommendations for Genelux?
The overall consensus recommendation for Genelux is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Genelux dividend yield?
Genelux does not currently pay a dividend.
Does Genelux pay a dividend?
Genelux does not currently pay a dividend.
When does Genelux next pay dividends?
Genelux does not currently pay a dividend.
How do I buy Genelux shares?
To buy shares in Genelux you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genelux?
As of the previous close price of $2.63, shares in Genelux had a market capitalisation of $99.24m.
Where are Genelux shares listed?
Here are the trading details for Genelux:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GNLX
What kind of share is Genelux?
Based on an overall assessment of its quality, value and momentum Genelux is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genelux share price forecast for 2025?
The analyst consensus target price for shares in Genelux is $18.00. That is 584.41% above the last closing price of $2.63.
Analysts covering Genelux currently have a consensus Earnings Per Share (EPS) forecast of -$1.02 for the next financial year.
Find out moreWhat is the trend in the Genelux share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genelux. Over the past six months, its share price has underperformed the S&P500 Index by -17.69%.
As of the last closing price of $2.63, shares in Genelux were trading -7.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genelux PE Ratio?
The Genelux PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genelux?
We do not have data on Genelux's directors